Drug intelligence / Profile preview

P-041

Development stage: Preclinical
Lead developer: Pangea Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

P-041 is a preclinical-stage ophthalmic non-steroidal anti-inflammatory drug (NSAID) being developed by Pangea Pharmaceuticals. It is intended for the treatment of ocular inflammation and pain. As an NSAID, its mechanism of action typically involves the inhibition of cyclooxygenase (COX) enzymes, which reduces the synthesis of prostaglandins that mediate inflammatory responses in the eye. The drug is currently in the preclinical development phase as part of Pangea's pipeline of ophthalmic therapies.

Brand names: Tyalia
Other names: aflibercept-CinnaGenCinnaGen aflibercept

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on P-041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-041.

Explore the full profile